Elisa Rush Port

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma
    Elisa Rush Port
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York, 10021, USA
    Ann Surg Oncol 13:677-84. 2006
  2. ncbi Results of MRI screening for breast cancer in high-risk patients with LCIS and atypical hyperplasia
    Elisa Rush Port
    Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg Oncol 14:1051-7. 2007
  3. ncbi Reoperative sentinel lymph node biopsy: a new frontier in the management of ipsilateral breast tumor recurrence
    Elisa Rush Port
    Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Ann Surg Oncol 14:2209-14. 2007
  4. doi Number of lymph nodes removed in sentinel lymph node-negative breast cancer patients is significantly related to patient age and tumor size: a new source of bias in morbidity assessment?
    Elisa Rush Port
    Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Evelyn H Lauder Breast Center, New York, New York 10065, USA
    Cancer 116:1987-91. 2010
  5. ncbi Reoperative sentinel lymph node biopsy: a new option for patients with primary or locally recurrent breast carcinoma
    Elisa Rush Port
    Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Am Coll Surg 195:167-72. 2002
  6. ncbi A prospective analysis of the effect of blue-dye volume on sentinel lymph node mapping success and incidence of allergic reaction in patients with breast cancer
    Tari A King
    Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Ann Surg Oncol 11:535-41. 2004
  7. doi Sentinel lymph node biopsy is successful and accurate in male breast carcinoma
    Laurie W Flynn
    Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Coll Surg 206:616-21. 2008
  8. doi Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer
    Elisabeth R Garwood
    Department of Surgery, University of California, San Francisco, CA, USA
    Breast Cancer Res Treat 119:137-44. 2010

Detail Information

Publications8

  1. ncbi 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma
    Elisa Rush Port
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York, 10021, USA
    Ann Surg Oncol 13:677-84. 2006
    ....
  2. ncbi Results of MRI screening for breast cancer in high-risk patients with LCIS and atypical hyperplasia
    Elisa Rush Port
    Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg Oncol 14:1051-7. 2007
    ..More data are needed to define the role of MRI screening for specific high-risk groups. We describe our experience with MRI screening in patients with atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS)...
  3. ncbi Reoperative sentinel lymph node biopsy: a new frontier in the management of ipsilateral breast tumor recurrence
    Elisa Rush Port
    Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Ann Surg Oncol 14:2209-14. 2007
    ..The question then arises: How best to manage the axilla in the setting of LR after previous BCT and SLN biopsy or axillary dissection (ALND)?..
  4. doi Number of lymph nodes removed in sentinel lymph node-negative breast cancer patients is significantly related to patient age and tumor size: a new source of bias in morbidity assessment?
    Elisa Rush Port
    Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Evelyn H Lauder Breast Center, New York, New York 10065, USA
    Cancer 116:1987-91. 2010
    ..They hypothesized that this variation is an unrecognized source of bias for studies examining the morbidity of SLN biopsy...
  5. ncbi Reoperative sentinel lymph node biopsy: a new option for patients with primary or locally recurrent breast carcinoma
    Elisa Rush Port
    Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Am Coll Surg 195:167-72. 2002
    ..Although previous breast or axillary surgery is often considered a contraindication to SLN biopsy, few data support this position. We report our experience with SLN biopsy in the reoperative setting...
  6. ncbi A prospective analysis of the effect of blue-dye volume on sentinel lymph node mapping success and incidence of allergic reaction in patients with breast cancer
    Tari A King
    Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Ann Surg Oncol 11:535-41. 2004
    ..This study examined whether the volume of isosulfan blue dye used in sentinel lymph node (SLN) mapping in breast cancer is related to the SLN identification rate or to the incidence of allergic reactions...
  7. doi Sentinel lymph node biopsy is successful and accurate in male breast carcinoma
    Laurie W Flynn
    Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Coll Surg 206:616-21. 2008
    ..Sentinel lymph node (SLN) biopsy minimizes this risk. We report results from the largest series of SLN biopsies for male breast cancer and compare this experience with that of female counterparts treated concurrently...
  8. doi Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer
    Elisabeth R Garwood
    Department of Surgery, University of California, San Francisco, CA, USA
    Breast Cancer Res Treat 119:137-44. 2010
    ..Effects were only evident in high grade tumors. These results support further evaluation of statins as chemoprevention for ER-negative high grade breast cancers...